Breast Tissue Dosimetry of PhIP (2-amino-1-methyl-6 phenylimidazo (4, 5b) pyridine) at Human-Relevant Exposures.
Abstract
The purpose of this research is to define the molecular events leading to the development of PhIP-induced breast tumors and to assess if PhIP exposure at human dietary levels present a human breast cancer risk. Our goals are to understand the effects of chemical exposure on adduct formation and metabolism, the types of adduct formed, how adducts are repaired and the ability of the breast to metabolize PhIP at exposure levels expected to occur via the human diet. To date, we have studied the pharmacokinetics of PhIP in both chronic feeding experiments and acute oral administrations of PhIP. We have continued studies to determine if PhIP is present in the breast tissue of lactating rats and if PhIP is passed from the milk to suckling pups. Additionally, we have investigated the effect of chlorophyllin treatment on the distribution of 14C-PhIP. We are in the process of characterizing the DNA adducts formed by the PhIP and are determining the effect of dose of PhIP on PhIP-DNA adduct formation in female rodents. We have now synthesized PhIP-DNA for antibody production. Furthermore, tritium AMS methodology has now been developed to the point that a double-labeling experiment can now be performed utilizing 2 different compounds.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1996
- Accession Number
- ADA321820
Entities
People
- Kenneth W. Turteltaub
Organizations
- United States Department of Energy